Hypertonic saline in treatment of pulmonary disease in cystic fibrosis

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Reeves, Emer P ^a   Molloy, Kevin ^a   Pohl, Kerstin ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; DORNASE ALFA; MANNITOL; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIINFLAMMATORY ACTIVITY; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHUS MUCUS; CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LUNG DISEASE; MUCOCILIARY CLEARANCE; MUCOLYSIS; NONHUMAN; REVIEW; TREATMENT OUTCOME; ADOLESCENT; ANIMAL; CHILD; ELASTICITY; GENETICS; INFANT; INFECTION; INFLAMMATION; LUNG; METABOLISM; MUCUS; MUTATION; NEWBORN; PHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY SYSTEM;

ADOLESCENT; ANIMALS; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ELASTICITY; HUMANS; INFANT; INFANT, NEWBORN; INFECTION; INFLAMMATION; LUNG; LUNG DISEASES; MUCOCILIARY CLEARANCE; MUCUS; MUTATION; RESPIRATORY SYSTEM; SALINE SOLUTION, HYPERTONIC;

EID: 84862317515     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/465230     Document Type: Review

References (95)

1. Wood R. E., Boat T. F., Doershuk C. F., Cystic fibrosis American Review of Respiratory Disease 1976 113 6 833 878
2. Zielenski J., Tsui L. C., Cystic fibrosis: genotypic and phenotypic variations Annual Review of Genetics 1995 29 777 807 (Pubitemid 26005359)
3. Boucher R. C., Stutts M. J., Knowles M. R., Na + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation Journal of Clinical Investigation 1986 78 5 1245 1252 (Pubitemid 17181562)
4. Stutts M. J., Canessa C. M., Olsen J. C., Hamrick M., Cohn J. A., Rossier B. C., Boucher R. C., CFTR as a cAMP-Dependent regulator of sodium channels Science 1995 269 5225 847 850
5. Matsui H., Grubb B. R., Tarran R., Randell S. H., Gatzy J. T., Davis C. W., Boucher R. C., Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease Cell 1998 95 7 1005 1015 (Pubitemid 29019052)
6. Hassett D. J., Korfhagen T. R., Irvin R. T., Schurr M. J., Sauer K., Lau G. W., Sutton M. D., Yu H., Hoiby N., Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies Expert Opinion on Therapeutic Targets 2010 14 2 117 130
7. Kahl B. C., Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease International Journal of Medical Microbiology 2010 300 8 514 519
8. Allen E. D., Cystic fibrosis: a decade of progress Drugs of Today 1999 35 11 835 848 (Pubitemid 30068842)
9. Boucher R. C., Evidence for airway surface dehydration as the initiating event in CF airway disease Journal of Internal Medicine 2007 261 1 5 16 (Pubitemid 46046468)
10. O'Sullivan B. P., Flume P., The clinical approach to lung disease in patients with cystic fibrosis Seminars in Respiratory and Critical Care Medicine 2009 30 5 505 513
11. Jones A. P., Wallis C., Dornase alfa for cystic fibrosis Cochrane Database of Systematic Reviews 2010 3 CD001127
12. Wark P., McDonald V. M., Nebulised hypertonic saline for cystic fibrosis Cochrane Database of Systematic Reviews 2009 2 CD001506
13. Robinson M., Regnis J. A., Bailey D. L., King M., Bautovich G. J., Bye P. T. P., Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis American Journal of Respiratory and Critical Care Medicine 1996 153 5 1503 1509 (Pubitemid 26141332)
14. Amin R., Subbarao P., Jabar A., Balkovec S., Jensen R., Kerrigan S., Gustafsson P., Ratjen F., Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function Thorax 2010 65 5 379 383
15. Ballmann M., Von Der Hardt H., Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis Journal of Cystic Fibrosis 2002 1 1 35 37
16. Eng P. A., Morton J., Douglass J. A., Riedler J., Wilson J., Robertson C. F., Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis Pediatric Pulmonology 1996 21 2 77 83 (Pubitemid 26098513)
17. Suri R., Metcalfe C., Lees B., Grieve R., Flather M., Normand C., Thompson S., Bush A., Wallis C., Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial The Lancet 2001 358 9290 1316 1321 (Pubitemid 33016495)
18. King M., Dasgupta B., Tomkiewicz R. P., Brown N. E., Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I American Journal of Respiratory and Critical Care Medicine 1997 156 1 173 177 (Pubitemid 27293184)
19. Tarran R., Grubb B. R., Parsons D., Picher M., Hirsh A. J., Davis C. W., Boucher R. C., The CF salt controversy: in vivo observations and therapeutic approaches Molecular Cell 2001 8 1 149 158 (Pubitemid 32772913)
20. Hebestreit A., Kersting U., Hebestreit H., Hypertonic saline inhibits luminal sodium channels in respiratory epithelium European Journal of Applied Physiology 2007 100 2 177 183 (Pubitemid 46681638)
21. Bergsson G., Reeves E. P., McNally P., Chotirmall S. H., Greene C. M., Greally P., Murphy P., O'Neill S. J., McElvaney N. G., LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline Journal of Immunology 2009 183 1 543 551
22. Havasi V., Hurst C. O., Briles T. C., Yang F., Bains D. G., Hassett D. J., Sorscher E., Inhibitory effects of hypertonic saline on P. aeruginosa motility Journal of Cystic Fibrosis 2008 7 4 267 269
23. Reeves E. P., Williamson M., O'Neill S. J., Greally P., McElvaney N. G., Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis American Journal of Respiratory and Critical Care Medicine 2011 183 11 1517 1523
24. Elkins M. R., Robinson M., Rose B. R., Harbour C., Moriarty C. P., Marks G. B., Belousova E. G., Xuan W., Bye P. T. P., A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis New England Journal of Medicine 2006 354 3 229 240 (Pubitemid 43113028)
25. Donaldson S. H., Bennett W. D., Zeman K. L., Knowles M. R., Tarran R., Boucher R. C., Mucus clearance and lung function in cystic fibrosis with hypertonic saline New England Journal of Medicine 2006 354 3 241 250 (Pubitemid 43113029)
26. Rogers D. F., Mucoactive agents for airway mucus hypersecretory diseases Respiratory Care 2007 52 9 1176 1193
27. Henke M. O., Renner A., Huber R. M., Seeds M. C., Rubin B. K., MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions American Journal of Respiratory Cell and Molecular Biology 2004 31 1 86 91 (Pubitemid 38888043)
28. Whitchurch C. B., Tolker-Nielsen T., Ragas P. C., Mattick J. S., Extracellular DNA required for bacterial biofilm formation Science 2002 295 5559 1487 (Pubitemid 34173996)
29. Brandt T., Breitenstein S., Von Der Hardt H., Tummler B., DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase Thorax 1995 50 8 880 882
30. Vasconcellos C. A., Allen P. G., Wohl M. E., Drazen J. M., Janmey P. A., Stossel T. P., Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin Science 1994 263 5149 969 971 (Pubitemid 24094561)
31. Kater A., Henke M. O., Rubin B. K., The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4 Annals of the New York Academy of Sciences 2007 1112 140 153 (Pubitemid 47598647)
32. Schwarzenberger P., Lei D., Freeman S. M., Ye P., Weinacker A., Theodossiou C., Summer W., Kolls J. K., Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma American Journal of Respiratory Cell and Molecular Biology 1998 19 2 333 337 (Pubitemid 128354198)
33. Hilliard T. N., Regamey N., Shute J. K., Nicholson A. G., Alton E. W. F. W., Bush A., Davies J. C., Airway remodelling in children with cystic fibrosis Thorax 2007 62 12 1074 1080 (Pubitemid 350206200)
34. Schulz T., Schumacher U., Prante C., Sextro W., Prehm P., Cystic fibrosis transmembrane conductance regulator can export hyaluronan Pathobiology 2010 77 4 200 209
35. Rahmoune H., Lamblin G., Lafitte J. J., Galabert C., Filliat M., Roussel P., Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis American Journal of Respiratory Cell and Molecular Biology 1991 5 4 315 320
36. Solic N., Wilson J., Wilson S. J., Shute J. K., Endothelial activation and increased heparan sulfate expression in cystic fibrosis American Journal of Respiratory and Critical Care Medicine 2005 172 7 892 898 (Pubitemid 41369074)
37. Khatri I. A., Bhaskar K. R., Lamont J. T., Sajjan S. U., Ho C. K. Y., Forstner J., Effect of chondroitinase ABC on purulent sputum from cystic fibrosis and other patients Pediatric Research 2003 53 4 619 627 (Pubitemid 36406732)
38. Goger B., Halden Y., Rek A., Msl R., Pye D., Gallagher J., Kungl A. J., Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites Biochemistry 2002 41 5 1640 1646 (Pubitemid 34112754)
39. Kuschen G. S. V., Coulin F., Power C. A., Proudfoot A. E. I., Hubbard R. E., Hoogewerf A. J., Wells T. N. C., Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses Biochemistry 1999 38 39 12959 12968
40. Bhattacharyya S., Solakyildirim K., Zhang Z., Chen M. L., Linhardt R. J., Tobacman J. K., Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate American Journal of Respiratory Cell and Molecular Biology 2010 42 1 51 61
41. Frates R. C., Kaizu T. T., Last J. A., Mucus glycoproteins secreted by respiratory epithelial tissue from cystic fibrosis patients Pediatric Research 1983 17 1 30 34 (Pubitemid 13223450)
42. Cheng P. W., Boat T. F., Cranfill K., Yankaskas J. R., Boucher R. C., Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis Journal of Clinical Investigation 1989 84 1 68 72 (Pubitemid 19170096)
43. Mohapatra N. K., Cheng P. W., Parker J. C., Paradiso A. M., Yankaskas J. R., Boucher R. C., Boat T. F., Alteration of sulfation of glycoconjugates, but not sulfate transport and intracellular inorganic sulfate content in cystic fibrosis airway epithelial cells Pediatric Research 1995 38 1 42 48
44. Robinson M., Hemming A. L., Regnis J. A., Wong A. G., Bailey D. L., Bautovich G. J., King M., Bye P. T. P., Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis Thorax 1997 52 10 900 903 (Pubitemid 27473934)
45. Dmello D., Nayak R. P., Matuschak G. M., Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis British Medical Journal 2011 1, article e000019
46. Laube B. L., Sharpless G., Carson K. A., Kelly A., Mogayzel Jr P. J., Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis BMC Pulmonary Medicine 2011 11, artice 45
47. Rosenfeld M., Davis S., Brumback L., Daniel S., Rowbotham R., Johnson R., McNamara S., Jensen R., Barlow C., Ratjen F., Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety Pediatric Pulmonology 2011 46 7 666 671
48. Dellon E. P., Donaldson S. H., Johnson R., Davis S. D., Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis Pediatric Pulmonology 2008 43 11 1100 1106
49. Tarran R., Button B., Picher M., Paradiso A. M., Ribeiro C. M., Lazarowski E. R., Zhang L., Collins P. L., Pickles R. J., Fredberg J. J., Boucher R. C., Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections Journal of Biological Chemistry 2005 280 42 35751 35759 (Pubitemid 41532768)
50. Enderby B., Doull I., Hypertonic saline inhalation in cystic fibrosissalt in the wound, or sweet success? Archives of Disease in Childhood 2007 92 3 195 196 (Pubitemid 46423784)
51. Buonpensiero P., De Gregorio F., Sepe A., Di Pasqua A., Ferri P., Siano M., Terlizzi V., Raia V., Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis Advances in Therapy 2010 27 11 870 878
52. Armstrong D. S., In celebration of expectoration: induced sputum indices as outcome measures in cystic fibrosis American Journal of Respiratory and Critical Care Medicine 2003 168 12 1412 1413 (Pubitemid 38037320)
53. Ho S. A., Ball R., Morrison L. J., Brownlee K. G., Conway S. P., Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis Pediatric Pulmonology 2004 38 1 82 87 (Pubitemid 38823762)
54. Aitken M. L., Greene K. E., Tonelli M. R., Burns J. L., Emerson J. C., Goss C. H., Gibson R. L., Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis Chest 2003 123 3 792 799 (Pubitemid 36315495)
55. Tabary O., Escotte S., Couetil J. P., Hubert D., Dusser D., Puchelle E., Jacquot J., High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I B kinase pathway in response to extracellular NaCl content Journal of Immunology 2000 164 6 3377 3384 (Pubitemid 30149004)
56. Hashimoto S., Matsumoto K., Gon Y., Nakayama T., Takeshita I., Horie T., Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial ceils through p38 mitogen-activated protein kinase American Journal of Respiratory and Critical Care Medicine 1999 159 2 634 640 (Pubitemid 29084892)
57. Carpagnano G. E., Barbaro M. P. F., Cagnazzo M., Di Gioia G., Giliberti T., Di Matteo C., Resta O., Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge Chest 2005 128 5 3159 3166 (Pubitemid 41698636)
58. Lee L., Kelher M. R., Moore E. E., Banerjee A., Silliman C. C., Hypertonic saline inhibits arachidonic acid priming of the human neutrophil Journal of Surgical Research 2012 174 1 24 28
59. Schaeffer V., Arbabi S., Garcia I. A., Knoll M. L., Cuschieri J., Bulger E. M., Maier R. V., Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline Journal of Surgical Research 2010 171 2 769 776
60. Gould N. S., Gauthier S., Kariya C. T., Min E., Huang J., Day B. J., Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury Respiratory Research 2010 11, article 119
61. Perks B., Shute J. K., DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics American Journal of Respiratory and Critical Care Medicine 2000 162 5 1767 1772
62. Vogelmeier C., Doring G., Neutrophil proteinases and rhDNase therapy in cystic fibrosis European Respiratory Journal 1996 9 11 2193 2195 (Pubitemid 26366640)
63. Frevert C. W., Kinsella M. G., Vathanaprida C., Goodman R. B., Baskin D. G., Proudfoot A., Wells T. N. C., Wight T. N., Martin T. R., Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue American Journal of Respiratory Cell and Molecular Biology 2003 28 4 464 472 (Pubitemid 36399368)
64. Kaneider N. C., Djanani A., Wiedermann C. J., Heparan sulfate proteoglycan-involving immunomodulation by cathelicidin antimicrobial peptides LL-37 and PR-39 The Scientific World Journal 2007 7 1832 1838 (Pubitemid 350277600)
65. Xiao W., Hsu Y. P., Ishizaka A., Kirikae T., Moss R. B., Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation Chest 2005 128 4 2316 2326 (Pubitemid 41507575)
66. Baraska-Rybak W., Sonesson A., Nowicki R., Schmidtchen A., Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids Journal of Antimicrobial Chemotherapy 2006 57 2 260 265 (Pubitemid 43160167)
67. Behrends V., Ryall B., Wang X., Bundy J. G., Williams H. D., Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance Molecular BioSystems 2010 6 3 562 569
68. Suri R., Marshall L. J., Wallis C., Metcalfe C., Bush A., Shute J. K., Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis American Journal of Respiratory and Critical Care Medicine 2002 166 3 352 355 (Pubitemid 34864425)
69. Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G., A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis New England Journal of Medicine 1992 326 12 812 815
70. Clunes M. T., Boucher R. C., Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis Current Opinion in Pharmacology 2008 8 3 292 299
71. Nash E. F., Stephenson A., Ratjen F., Tullis E., Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis Cochrane Database of Systematic Reviews 2009 1 CD007168
72. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L., Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum Proceedings of the National Academy of Sciences of the United States of America 1990 87 23 9188 9192 (Pubitemid 120030590)
73. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E., Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis New England Journal of Medicine 1994 331 10 637 642 (Pubitemid 24276863)
74. Ramsey B. W., Astley S. J., Aitken M. L., Burke W., Colin A. A., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Schidlow D. V., Wilmott R. W., Wohl M. E., Meyerson L. J., Shak S., Fuchs H., Smith A. L., Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis American Review of Respiratory Disease 1993 148 1 145 151 (Pubitemid 23187234)
75. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M., Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis The Lancet 1993 342 8865 199 202 (Pubitemid 23214635)
76. Suri R., Wallis C., Bush A., Thompson S., Normand C., Flather M., Grieve R., Metcalfe C., Lees B., A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment 2002 6 34 1 60
77. Daviskas E., Anderson S. D., Brannan J. D., Chan H. K., Eberl S., Bautovich G., Inhalation of dry-powder mannitol increases mucociliary clearance European Respiratory Journal 1997 10 11 2449 2454 (Pubitemid 28048614)
78. Daviskas E., Anderson S. D., Eberl S., Chan H. K., Bautovich G., Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis American Journal of Respiratory and Critical Care Medicine 1999 159 6 1843 1848 (Pubitemid 29275053)
79. Jaques A., Daviskas E., Turton J. A., McKay K., Cooper P., Stirling R. G., Robertson C. F., Bye P. T. P., LeSouf P. N., Shadbolt B., Anderson S. D., Charlton B., Inhaled mannitol improves lung function in cystic fibrosis Chest 2008 133 6 1388 1396 (Pubitemid 351892995)
80. Bilton D., Robinson P., Cooper P., Gallagher C. G., Kolbe J., Fox H., Jaques A., Charlton B., Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study European Respiratory Journal 2011 38 5 1071 1080
81. Robinson M., Daviskas E., Eberl S., Baker J., Chan H. K., Anderson S. D., Bye P. T. P., The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study European Respiratory Journal 1999 14 3 678 685 (Pubitemid 29479736)
82. Kuzik B. A., Al Qadhi S. A., Kent S., Flavin M. P., Hopman W., Hotte S., Gander S., Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants Journal of Pediatrics 2007 151 3 266
83. Kellett F., Redfern J., McL Niven R., Evaluation of nebulised hypertonic saline (7) as an adjunct to physiotherapy in patients with stable bronchiectasis Respiratory Medicine 2005 99 1 27 31 (Pubitemid 40017380)
84. Kellett F., Robert N. M., Nebulised 7 hypertonic saline improves lung function and quality of life in bronchiectasis Respiratory Medicine 2011 105 12 1831 1835
85. Al-Ansari K., Sakran M., Davidson B. L., El Sayyed R., Mahjoub H., Ibrahim K., Nebulized 5 or 3 hypertonic or 0.9 saline for treating acute bronchiolitis in infants Journal of Pediatrics 2010 157 4 630 634
86. Bathoorn E., Liesker J., Postma D., Koter G., Van Oosterhout A. J. M., Kerstjens H. A. M., Safety of sputum induction during exacerbations of COPD Chest 2007 131 2 432 438 (Pubitemid 46280403)
87. Fahy J. V., Boushey H. A., Lazarus S. C., Mauger E. A., Cherniack R. M., Chinchilli V. M., Craig T. J., Drazen J. M., Ford J. G., Fish J. E., Israel E., Kraft M., Lemanske R. F., Martin R. J., McLean D., Peters S. P., Sorkness C., Szefler S. J., Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study American Journal of Respiratory and Critical Care Medicine 2001 163 6 1470 1475 (Pubitemid 32506618)
88. Rand Sutherland E., Sputum induction in COPDit's safe, so now what do we do? Journal of Chronic Obstructive Pulmonary Disease 2006 3 2 73 74
89. Toungoussova O., Migliori G. B., Foschino Barbaro M. P., Esposito L. M., Dragonieri S., Carpagnano G. E., Salerno F. G., Neri M., Spanevello A., Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease Respiratory Medicine 2007 101 7 1543 1548 (Pubitemid 46838599)
90. Wilson A. M., Leigh R., Hargreave F. E., Pizzichini M. M. M., Pizzichini E., Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease Journal of Chronic Obstructive Pulmonary Disease 2006 3 2 89 93 (Pubitemid 43739180)
91. App E. M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M., Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis European Respiratory Journal 2002 19 2 294 302 (Pubitemid 34162831)
92. Elkins M. R., Bye P. T. P., Inhaled hypertonic saline as a therapy for cystic fibrosis Current Opinion in Pulmonary Medicine 2006 12 6 445 452 (Pubitemid 44624606)
93. Wark P. A., McDonald V., Jones A. P., Nebulised hypertonic saline for cystic fibrosis Cochrane Database of Systematic Reviews 2005 3 CD001506
94. Wills P. J., Inhaled mannitol in cystic fibrosis Expert Opinion on Investigational Drugs 2007 16 7 1121 1126 (Pubitemid 47074166)
95. Boucher R. C., Cystic fibrosis: a disease of vulnerability to airway surface dehydration Trends in Molecular Medicine 2007 13 6 231 240 (Pubitemid 46836874)